<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618769</url>
  </required_header>
  <id_info>
    <org_study_id>2021-117</org_study_id>
    <nct_id>NCT05618769</nct_id>
  </id_info>
  <brief_title>Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants</brief_title>
  <acronym>LONG LOVE</acronym>
  <official_title>Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants (Dutch: Naar Levenslang Gezonde LONGen: Een multidiscipLinair zOrgpad Voor te Vroeg Geboren kindEren)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting BeterKeten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Revenio Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Franciscus Gasthuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 8% of all births occur between 30-36 weeks of gestation ('moderate-late'&#xD;
      prematurity). Respiratory tract infections (RTI) and wheezing illnesses disproportionally&#xD;
      affect preterm infants resulting in a 1.5-2 fold higher hospitalisation rate during the first&#xD;
      years of life compared to term born children. Besides prematurity, several other postnatal&#xD;
      modifiable influencing factors are associated with increased risk of respiratory morbidity&#xD;
      and impaired pulmonary development. These factors include RTI, rapid weight gain, air&#xD;
      pollution, tobacco smoke exposition, vitamin D deficiency, maternal stress and antibiotic&#xD;
      usage. The investigators hypothesize that a follow-up program aiming at prevention of&#xD;
      modifiable influencing factors can reduce respiratory morbidity in moderate and late&#xD;
      prematurity. Objectives: To reduce respiratory disease burden in moderate-late preterm&#xD;
      infants in the first 18 months of life&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      Approximately 8% of all births occur between 30-36 weeks of gestation (moderate-late&#xD;
      prematurity). Respiratory tract infections (RTI) and wheezing illnesses disproportionally&#xD;
      affect preterms, resulting in a 1.5-2 fold higher hospitalization rate during the first years&#xD;
      of life compared to term-born children. Besides prematurity, several other modifiable&#xD;
      influencing factors are associated with increased risk of respiratory morbidity and impaired&#xD;
      pulmonary development. These factors include rapid weight gain and obesity at an early age,&#xD;
      tobacco smoke exposure, air pollution, microbiome composition, and recurrent RTI.&#xD;
&#xD;
      To promote optimal lung health and development in moderate-late preterm infants, increased&#xD;
      respiratory health surveillance and protection against RTI in early life might be crucial.&#xD;
      Previous research has shown that the introduction of a multidisciplinary follow-up framework&#xD;
      in children with bronchopulmonary dysplasia resulted in a significant reduction in hospital&#xD;
      readmissions.&#xD;
&#xD;
      Despite the burden of respiratory disease, moderate to late preterms do not currently receive&#xD;
      standardised respiratory follow-up care. With LONG LOVE, the investigators introduce a novel&#xD;
      follow-up framework tailored for preterms and designed to improve respiratory health. As the&#xD;
      risk of the onset of pulmonary disease is further increased by postnatal factors such as&#xD;
      tobacco smoke exposure, air pollution and RTI, our main focus is the detection and treatment&#xD;
      of these modifiable influencing factors. LONG LOVE incorporates eHealth and new technology in&#xD;
      order to measure pulmonary function and air quality. Intervention strategies include&#xD;
      counseling on nutrition, lifestyle, medication, and improving indoor air quality.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      The project's overarching aim is to diminish respiratory disease burden in moderate-late&#xD;
      preterm born infants in their first 18 months of life.&#xD;
&#xD;
      The investigators have formulated the following specific objectives:&#xD;
&#xD;
        1. Determine whether the introduction of our follow-up framework will reduce the number&#xD;
           and/or severity of RTI and wheezing episodes in the first 18 months of life&#xD;
&#xD;
        2. Analyse the predictive value of nocturnal impedance pneumatography on lower respiratory&#xD;
           symptoms in prematurely born infants &lt; 1 year of age. Further, correlate this novel tool&#xD;
           to other forms of pulmonary function analyses such as the Lung Clearance Index and&#xD;
           Hypoxic Challenge Test.&#xD;
&#xD;
        3. Conduct a cost-benefit analysis after the implementation of our framework.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      The investigators intend a quasi-experimental design based on a non-randomized cluster trial,&#xD;
      in which moderate-late preterm-born infants will be allocated to the intervention or control&#xD;
      group based on the location of birth. This design was chosen based on the limited amount of&#xD;
      participating clusters and feasibility. As a quasi-experimental design can result in&#xD;
      confounding by cluster and to increase internal validity, subjects of the control and&#xD;
      intervention groups will be demographically matched at baseline[54,55]&#xD;
&#xD;
      Cluster 1 Consists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and&#xD;
      will be allocated to the intervention group, receiving additional (in addition to the current&#xD;
      standard of care) follow-up in accordance with our newly developed framework to identify&#xD;
      modifiable influencing factors compromising pulmonary health using validated questionnaires,&#xD;
      weekly monitoring of respiratory symptoms as reported by parents using an app, in- and&#xD;
      outdoor air quality measurements and non-invasive pulmonary function measurements based on&#xD;
      impedance pneumatography.&#xD;
&#xD;
      In case of any modifiable influencing factors, appropriate lifestyle and/or medical&#xD;
      interventions will be undertaken.&#xD;
&#xD;
      Cluster 2 (control) Consist of participants born in Maasstad Ziekenhuis (MSZ) and Albert&#xD;
      Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up.&#xD;
&#xD;
      Parents are requested to provide informed consent for the registration of outcome&#xD;
      measurements and requested to complete validated questionnaires. Data on utilization of&#xD;
      medical services will be inquired to avoid recall bias.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Moderate-late preterm infants (GA 30+0-35+6 weeks) without other significant underlying&#xD;
      syndromal, cardial, and/or pulmonal morbidities.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Follow-up regimen after premature birth using the LONG LOVE framework:&#xD;
&#xD;
      Identification of modifiable influencing factors Five study visits are scheduled to monitor&#xD;
      health status on 1-1.5*, 3, 6, 12 and 18 months of age. These visits are planned in&#xD;
      conjunction with regular follow-up examinations. Well-being and other potential risks will be&#xD;
      determined by: growth, nutritional problems, feeding mode, pets, maternal stress (Edinburgh&#xD;
      Postnatal Depression Scale questionnaire), sleep (Infant Sleep Questionnaire (ISQ)), tobacco&#xD;
      smoke exposure, daycare attendance, the existence of siblings.&#xD;
&#xD;
      Air quality measurements Outdoor air analysis will be obtained using national and regional&#xD;
      air measurement networks (RIVM Luchtmeetnet; DCMR Milieudienst Rijnmond). This network&#xD;
      consists of a large number of air quality measurement sites, measuring harmful substances:&#xD;
      nitric oxides (NOx, NO2), particulate matter (PM2.5, PM10), and ozone. Measurements will be&#xD;
      taken from a station located nearest to the home address of the participant. Measurements are&#xD;
      provided as publicly accessible data by the Dutch government.&#xD;
&#xD;
      Indoor air quality will be analyzed using a commercially available environment monitor. This&#xD;
      device offers real-time monitoring of air quality factors such as temperature, humidity,&#xD;
      particulate matter (PM1, PM2,5, PM10), carbon dioxide, and volatile organic compounds (VOCs).&#xD;
      Air quality measurements will be taken from the living room or participants' sleeping room&#xD;
      for a total duration of 1 year.&#xD;
&#xD;
      Pulmonary function analysis Pulmonary function analysis using impedance pneumatography will&#xD;
      be measured at 3, 6, and 12 months of age during two consecutive nights using the Ventica&#xD;
      recorder.&#xD;
&#xD;
      eHealth All parents are requested to install a newly developed application on their phones&#xD;
      when enrolled in the study. The app is used for a weekly evaluation of respiratory symptoms.&#xD;
      The following clinical parameters/variables will be monitored throughout the study:&#xD;
      Respiratory health will be determined as follows: physician-diagnosed lower RTI- and wheezing&#xD;
      episodes, hospitalizations for respiratory problems, clinical variables such as other&#xD;
      respiratory episodes, common colds, medication use (bronchodilators, corticosteroids,&#xD;
      antibiotics).&#xD;
&#xD;
      Interventions Aside from identification of potential health risks, our framework is designed&#xD;
      to offer interventions if required. At baseline, all participants receive verbal and written&#xD;
      information (App) defining potential hazardous factors regarding pulmonary development and&#xD;
      overall health. In the event of pulmonary symptoms, parents are requested to consult a&#xD;
      doctor.&#xD;
&#xD;
      In case of modifiable influencing factors, the following lifestyle and medical interventions&#xD;
      will be performed:&#xD;
&#xD;
      In the case of 1.5 SDS weight gain or loss (based on birth weight), nutritional advice is&#xD;
      provided by a paediatrician and follow-up by primary infant health care services.&#xD;
&#xD;
      In case of EPDS-scores â‰¥12 (stress-depression mother) consultation by lifestyle coach or&#xD;
      community worker (Kleine Heldenhuis). If required, referral to general practitioner or&#xD;
      psychologist/psychiatrist.&#xD;
&#xD;
      If sleep quality is affected (ISQ &gt;12): medical advice and sleep training is provided by a&#xD;
      paediatrician and/or primary infant health care services In the case of pulmonary symptoms:&#xD;
      clinical assessment by a general practitioner or paediatrician. Administration of antibiotics&#xD;
      according to Dutch board of Paediatricians guideline, optionally C-reactive protein&#xD;
      measurement to prevent unnecessary antibiotics use If one or both caretakers are smoking:&#xD;
      consultation by a general practitioner and primary infant health care services to provide&#xD;
      stop-smoking services In case of inferior indoor air quality: visit by PhD-student or&#xD;
      pulmonary care nurse to instruct how to improve air quality Optimal identification and&#xD;
      treatment of comorbidity: gastro-oesophageal re ux disease, vitamin D deficiency, iron&#xD;
      deficiency anaemia by paediatrician Active consultancy and treatment of nasal congestion&#xD;
      using saline and-or xylometazoline by paediatrician Bronchodilator/broncholytic (salbutamol)&#xD;
      trial by pediatrician in event of recurrent clinical bronchial obstruction and/or abnormal&#xD;
      expiratory variability index using impedance pneumatography. If bronchodilator therapy is&#xD;
      regularly required (a minimum of 2 episodes 2-3 days of week for a minimal duration of two&#xD;
      weeks), inhaled corticosteroids can be prescribed.&#xD;
&#xD;
      These interventions are performed by both primary and secondary healthcare professionals&#xD;
      (including the PhD-student who has an active role in patient management). Primary infant&#xD;
      healthcare services operating in the Rijnmond region will fulfill an important role and are&#xD;
      directly involved with the implementation of this framework.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Quasi-experimental design based on a non-randomized cluster trial, in which moderate-late preterm born infants will be allocated to the intervention or control group based on location of neonatal care. This design was chosen based on the limited amount of participating clusters and feasibility. As a quasi-experimental design can result in confounding by cluster and to increase internal validity, subjects of the control and intervention groups will be demographically matched at baseline</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lower Respiratory Tract Infections (RTI)</measure>
    <time_frame>18 months of life</time_frame>
    <description>Total number of physician diagnosed lower RTI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of wheezing episodes</measure>
    <time_frame>18 months of life</time_frame>
    <description>Total number of physician diagnosed wheezing episodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to first lower RTI or wheezing episode</measure>
    <time_frame>18 months of life</time_frame>
    <description>Elapsed time from birth until first RTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of RTI</measure>
    <time_frame>18 months of life</time_frame>
    <description>Total number of RTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of wheezing episodes</measure>
    <time_frame>18 months of life</time_frame>
    <description>total number of wheezing episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of viruses (in case of hospital admission)</measure>
    <time_frame>18 months of life</time_frame>
    <description>PCR measured viral distribution in case of hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medication use</measure>
    <time_frame>18 months of life</time_frame>
    <description>Number of prescriptions (bronchodilators, corticosteroids, antibiotics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung function as measured by expiratory variability index (EVI)</measure>
    <time_frame>3, 6, 12 months of age</time_frame>
    <description>Average EVI in preterm infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of expiratory variability index in moderate/late prematurity compared to term cohort (reference cohort from other center)</measure>
    <time_frame>3, 6, 12 months of age</time_frame>
    <description>Average EVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between expiratory variability index and Lung Capacity Index and Hypoxic Challenge Test</measure>
    <time_frame>6 months of age</time_frame>
    <description>EVI correlation with LCI and HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between expiratory variability index and number of RTI/wheezing</measure>
    <time_frame>18 months of life</time_frame>
    <description>association between low expiratory variability index and number of RTI/wheezing-rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of outdoor air quality</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of outdoor air quality using sensor and satellite data for increased spatial resolution: exceedance of health-based criteria (WHO, EU); outdoor-indoor pollution relationship; and association between air pollution and respiratory complaints/hospital admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>indoor air quality</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of indoor air quality using low-cost air quality sensors: exceedance of health-based criteria (WHO, EU), outdoor-indoor pollution relations; effect of direct feedback and strategies on optimization of indoor air quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preschool Children Quality of Life</measure>
    <time_frame>12 and 18 months of life</time_frame>
    <description>by TNO-AZL Preschool Children Quality of Life (TAPQOL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs of framework</measure>
    <time_frame>18 months of life</time_frame>
    <description>Total costs of framework consist of healthcare costs (medication and other healthcare costs), productivity costs and patient costs. Healthcare use will be assessed with the institute of Medical Technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ)supplemented with information on respiratory-related medication use, outpatient clinic visits and diagnostics extracted from the medical chart. Patient costs consisted of informal care and were measured using the iMTA MCQ. Healthcare and patient costs were valued according to the Dutch guideline. Productivity losses were estimated with the iMTA Productivity Cost Questionnaire (iPCQ)24 every 12 weeks. Productivity loss consists of absenteeism (sick leave), presenteeism (reduced effectiveness at work) and loss of unpaid work and will be evaluated using the iPCQ questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Care-related Quality of Life</measure>
    <time_frame>18 months of life</time_frame>
    <description>Measuring and valuating the impact of providing informal care on caregivers using the CarerQoL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of framework</measure>
    <time_frame>18 months of life</time_frame>
    <description>Societal costs as specified under 15 will be compared between both intervention and control groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Premature Birth</condition>
  <condition>Respiratory Disease</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Preterm Birth</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Pollution Related Respiratory Disorder</condition>
  <condition>Pollution; Exposure</condition>
  <condition>Smoking Cessation</condition>
  <condition>Health-Related Behavior</condition>
  <condition>RSV Infection</condition>
  <condition>RSV Pneumonia</condition>
  <condition>Bronchial Hyperreactivity</condition>
  <condition>Telemedicine</condition>
  <condition>eHealth</condition>
  <arm_group>
    <arm_group_label>Intervention (LONG LOVE Framework)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consists of participants born in Franciscus Gasthuis (FG) and/or Vlietland (FV) and will be allocated to the intervention group, receiving additional (in addition to current standard of care) follow-up in accordance with our newly developed framework to identify modi able influencing factors compromising pulmonary health using validated questionnaires, weekly monitoring of respiratory symptoms as reported by parents using an app, in- and outdoor air quality measurements and non-invasive pulmonary function measurements based on impedance pneumatography.&#xD;
In case of any modi able influencing factors, appropriate lifestyle and/or medical interventions will be undertaken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Consist of participants born in Maasstad Ziekenhuis (MSZ) and Albert Schweitzer Ziekenhuis (ASZ) and will receive standard of care follow-up.&#xD;
Parents are requested to provide informed consent for the registration of outcome measurements and requested to complete validated questionnaires. Data on utilization of medical services will be inquired to avoid recall bias.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>LONG LOVE Framework</intervention_name>
    <description>In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.</description>
    <arm_group_label>Intervention (LONG LOVE Framework)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate-late preterm infants (GA 30+0 - 35+6 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bronchopulmonary dysplasia (BPD)&#xD;
&#xD;
          -  congenital diaphragmatic hernia (CHD),&#xD;
&#xD;
          -  congenital pulmonary disorders&#xD;
&#xD;
          -  hemodynamic significant cardiac disease&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  severe failure to thrive;&#xD;
&#xD;
          -  birth asphyxia with poor neurological outcome&#xD;
&#xD;
          -  syndromic or other severe congenital disorders with decreased life expectancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerdien Tramper, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franciscus Gasthuis &amp; Vlietland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kishan Tsang, MD</last_name>
    <phone>+31(0)683278272</phone>
    <email>k.tsang@franciscus.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerdien Tramper, MD, PhD</last_name>
    <phone>+31(10)4617126</phone>
    <email>g.tramper@franciscus.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Franciscus Gasthuis &amp; Vlietland</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kishan Tsang, MD</last_name>
      <phone>+31(0)683278272</phone>
      <email>kishtsang@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gerdien Tramper, MD, PhD</last_name>
      <phone>+31(0)104617126</phone>
      <email>g.tramper@franciscus.nl</email>
    </contact_backup>
    <investigator>
      <last_name>I. de Kleer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M.W.H Pijnenburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M.G.A. Baartmans</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>E.A. Smit-Kleinlugtenbeld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://longlovestudie.nl</url>
    <description>Official Research Website (Dutch)</description>
  </link>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>October 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate preterm</keyword>
  <keyword>Late preterm</keyword>
  <keyword>Post-Prematurity Respiratory Disease</keyword>
  <keyword>Prematurity Associated Lung Disease</keyword>
  <keyword>eHealth</keyword>
  <keyword>mHeath</keyword>
  <keyword>Follow-up</keyword>
  <keyword>Respiratory Disease</keyword>
  <keyword>Air pollution</keyword>
  <keyword>Value Based Health Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

